Recent work has reported that the activation of thep53 pathway in primary cells hampers the efficiencyof genome editing by CRISPR/Cas9 via induction ofapoptosis or cell cycle arrest. These findings highlightthe importance of wholly comprehending cellularresponses to programmable nucleases intherapeutically relevant cell types to fulfill the promiseof genome editing for therapeutic applications forhuman diseases.